ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 142

Antiphospholipid Antibodies Prevalence in Women with Late Pregnancy Complication and Low-Risk for Chromosomal Abnormalities

Silvia Grazietta Foddai1, Massimo Radin 1, Elena Rubini 1, Irene Cecchi 1, Savino Sciascia 2, Dario Roccatello 1, Elisa Menegatti 1, Silvia Gaito 1, Luca Marozio 1, Tilde Manetta 1 and Giulio Mengozzi 1, 1University of Turin, Turin, Italy, 2Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: antibodies and Diagnostic Tests, Antiphospholipid antibodies, antiphospholipid syndrome, pregnancy

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Session Title: Antiphospholipid Syndrome Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: While current guidelines help defining correct pregnancy standard of care for patients with systemic lupus erythematosus andantiphospholipid syndrome (APS),little is known about the significance of antiphospholipid antibodies (aPL) detection during pregnancy and their association with clinical manifestations of the syndrome in women without history of rheumatic disease.

In this context, we aimed to retrospectively investigate the prevalence of aPL and late-onset pregnancy complications (LO-PC) in a cohort of women with low risk of chromosomal abnormalities.

Methods: For the purpose of this study, we retrospectively collected data from a number of patients ever pregnant attending the S. Anna University Clinic (Turin, Italy) from August 2017 to August 2018, that were found to be negative for triple test and fetal abnormalities and who experienced LO-PC. aPL testing was performed on serum samples derived from pregnancy screening test collected during the fourth month of gestation. aPL detection was performed using both ELISA assay (INOVA Diagnostic) and chemiluminescent immunoassay (INOVA Diagnostic) for the semi-quantitative measurement of antibodies -comprehensive of IgG, IgM, and IgA isotypes for anticardiolipin (aCL) and anti-β2-glycoprotein I (β2GPI), β2GPI domain I, and anti-phosphatidylserine/prothrombin (aPS/PT) IgG and IgM.

Results: Fifty-nine patients met the inclusion criteria of the study. Pregnancy complications were as follows: 27 (46%) patients developed preeclampsia, 1 eclampsia, 16 (27%) manifested gestational diabetes, 32 (54%) gestational hypertension, 6 (10%) experienced HELLP syndrome, and 8 (14%) intrauterine growth restriction. Obstetric and post-partum complications were as follows: 12 (20%) patients developed hypertensive crisis, 6(10%) patients developed post-partum hemorrhage, 1 patient developed hypertensive crisis, acute renal failure, and acute respiratory insufficiency concomitantly. Placental histologic examination, when performed, showed that the most frequent histologic finding was placental malperfusion (19 patients, 32%), followed by 3 fetal thrombotic vasculopathy (5%), 1 subacute villitis, 1 subacute deciduitis, and 1 case of chronic villitis of unknown etiology. Nineteen women (32%) were aPL positive, in detail: 15 showed a single positivity (6 aPS/PT IgM, 1 aPS/PT IgG, 8 aCL IgG), 3 double positivity (aCL IgG, aPS/PT IgM), and one triple positivity (aCL IgG, β2GPI IgG, andaPS/PT IgM). Of interest, patients with aPL positivity had significantly lower life births rates (84% vs. 98%, p< 0.05). Table 1 shows fetal, maternal outcomes, post-partum complications, and placental histologic findings.

Conclusion: In our experience, the prevalence of aPL in women with LO-PC at low-risk for chromosomal abnormalities was as high as 32%. Our data suggest that testing for both criteria and extra criteria aPL could improve the diagnostic accuracy to identify LO-PC.

Fetal and maternal pregnancy outcomes, obstetric complications and placental findings.
aPL means antiphospholipid antibodies; IUGR, intrauterine growth restriction.


Disclosure: S. Foddai, None; M. Radin, None; E. Rubini, None; I. Cecchi, None; S. Sciascia, None; D. Roccatello, None; E. Menegatti, None; S. Gaito, None; L. Marozio, None; T. Manetta, None; G. Mengozzi, None.

To cite this abstract in AMA style:

Foddai S, Radin M, Rubini E, Cecchi I, Sciascia S, Roccatello D, Menegatti E, Gaito S, Marozio L, Manetta T, Mengozzi G. Antiphospholipid Antibodies Prevalence in Women with Late Pregnancy Complication and Low-Risk for Chromosomal Abnormalities [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/antiphospholipid-antibodies-prevalence-in-women-with-late-pregnancy-complication-and-low-risk-for-chromosomal-abnormalities/. Accessed February 6, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antiphospholipid-antibodies-prevalence-in-women-with-late-pregnancy-complication-and-low-risk-for-chromosomal-abnormalities/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences